<!DOCTYPE html>
<!-- This site was created with Wowchemy. https://www.wowchemy.com -->
<!-- Last Published: October 13, 2022 --><html lang="en-us" >


<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <meta http-equiv="X-UA-Compatible" content="IE=edge" />
  
  
  
    <meta name="generator" content="Wowchemy 5.7.0 for Hugo" />
  

  
  












  
  










  







  
  
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin />
  

  
  
  
    
      
      <link rel="preload" as="style" href="https://fonts.googleapis.com/css2?family=Montserrat:wght@400;700&family=Roboto+Mono&family=Roboto:wght@400;700&display=swap">
      <link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Montserrat:wght@400;700&family=Roboto+Mono&family=Roboto:wght@400;700&display=swap" media="print" onload="this.media='all'">
    
  

  
  

  
  
    
    <script src="/js/mathjax-config.js"></script>
  

  

  <link rel="stylesheet" href="/css/vendor-bundle.min.16f785cdb553c8c4431db6775122af35.css" media="print" onload="this.media='all'">

  
  
  
    
    
      <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/academicons@1.9.2/css/academicons.min.css" integrity="sha512-KlJCpRsLf+KKu2VQa5vmRuClRFjxc5lXO03ixZt82HZUk41+1I0bD8KBSA0fY290ayMfWYI9udIqeOWSu1/uZg==" crossorigin="anonymous" media="print" onload="this.media='all'">
    

    
    
    
    
      
      
    
    
    

    
    
    

    

    
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
        <script src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-chtml.js" integrity="" crossorigin="anonymous" async></script>
      
    
      
      

      
      

      
    
      
      

      
      

      
    
  

  
  
  
  
  
  
  <link rel="stylesheet" href="/css/wowchemy.e5d7adca760216d3b7e28ea434e81f6f.css" />

  
  
  
  
  
  
  
    
    
    <link rel="stylesheet" href="/css/libs/chroma/github-light.min.css" title="hl-light" media="print" onload="this.media='all'" >
    <link rel="stylesheet" href="/css/libs/chroma/dracula.min.css" title="hl-dark" media="print" onload="this.media='all'" disabled>
  

  
  


























  
  
  






  <meta name="author" content="Alessio Crippa" />





  

<meta name="description" content="PURPOSE Tamoxifen prevents breast cancer in high-risk women and reduces mortality in the adjuvant setting. Mammographic density change is a proxy for tamoxifen therapy response. We tested whether lower doses of tamoxifen were noninferior to reduce mammographic density and associated with fewer symptoms. PATIENTS AND METHODS Women, 40-74 years of age, participating in the Swedish mammography screening program were invited to the 6-month double-blind six-arm randomized placebo-controlled noninferiority dose-determination KARISMA phase II trial stratified by menopausal status (EudraCT 2016-000882-22). In all, 1,439 women were accrued with 1,230 participants accessible for intention-to-treat analysis. The primary outcome was proportion of women treated with placebo, 1, 2.5, 5, and 10 mg whose mammographic density decreased at least as much as the median reduction in the 20 mg arm. The noninferior margin was 17%. Secondary outcome was reduction of symptoms. Post hoc analyses were performed by menopausal status. Per-protocol population and full population were analyzed in sensitivity analysis. RESULTS The 1,439 participants, 566 and 873 pre- and postmenopausal women, respectively, were recruited between October 1, 2016, and September 30, 2019. The participants had noninferior mammographic density reduction following 2.5, 5, and 10 mg tamoxifen compared with the median 10.1% decrease observed in the 20 mg group, a reduction confined to premenopausal women. Severe vasomotor symptoms (hot flashes, cold sweats, and night sweats) were reduced by approximately 50% in the 2.5, 5, and 10 mg groups compared with the 20 mg group. CONCLUSION Premenopausal women showed noninferior magnitude of breast density decrease at 2.5 mg of tamoxifen, but fewer side effects compared with the standard dose of 20 mg. Future studies should test whether 2.5 mg of tamoxifen reduces the risk of primary breast cancer." />



<link rel="alternate" hreflang="en-us" href="https://6346b314635e8e77d95c6d10--luminous-stardust-9f8aab.netlify.app/publication/2021-06-10_low-dose_tamoxifen_f/" />
<link rel="canonical" href="https://6346b314635e8e77d95c6d10--luminous-stardust-9f8aab.netlify.app/publication/2021-06-10_low-dose_tamoxifen_f/" />



  <link rel="manifest" href="/manifest.webmanifest" />



<link rel="icon" type="image/png" href="/media/icon_hu0b7a4cb9992c9ac0e91bd28ffd38dd00_9727_32x32_fill_lanczos_center_3.png" />
<link rel="apple-touch-icon" type="image/png" href="/media/icon_hu0b7a4cb9992c9ac0e91bd28ffd38dd00_9727_180x180_fill_lanczos_center_3.png" />

<meta name="theme-color" content="#1565c0" />










  
  






<meta property="twitter:card" content="summary" />

  <meta property="twitter:site" content="@wowchemy" />
  <meta property="twitter:creator" content="@wowchemy" />
<meta property="twitter:image" content="https://6346b314635e8e77d95c6d10--luminous-stardust-9f8aab.netlify.app/media/icon_hu0b7a4cb9992c9ac0e91bd28ffd38dd00_9727_512x512_fill_lanczos_center_3.png" />
<meta property="og:site_name" content="Alessio Crippa" />
<meta property="og:url" content="https://6346b314635e8e77d95c6d10--luminous-stardust-9f8aab.netlify.app/publication/2021-06-10_low-dose_tamoxifen_f/" />
<meta property="og:title" content="Low-Dose Tamoxifen for Mammographic Density Reduction: A Randomized Controlled Trial | Alessio Crippa" />
<meta property="og:description" content="PURPOSE Tamoxifen prevents breast cancer in high-risk women and reduces mortality in the adjuvant setting. Mammographic density change is a proxy for tamoxifen therapy response. We tested whether lower doses of tamoxifen were noninferior to reduce mammographic density and associated with fewer symptoms. PATIENTS AND METHODS Women, 40-74 years of age, participating in the Swedish mammography screening program were invited to the 6-month double-blind six-arm randomized placebo-controlled noninferiority dose-determination KARISMA phase II trial stratified by menopausal status (EudraCT 2016-000882-22). In all, 1,439 women were accrued with 1,230 participants accessible for intention-to-treat analysis. The primary outcome was proportion of women treated with placebo, 1, 2.5, 5, and 10 mg whose mammographic density decreased at least as much as the median reduction in the 20 mg arm. The noninferior margin was 17%. Secondary outcome was reduction of symptoms. Post hoc analyses were performed by menopausal status. Per-protocol population and full population were analyzed in sensitivity analysis. RESULTS The 1,439 participants, 566 and 873 pre- and postmenopausal women, respectively, were recruited between October 1, 2016, and September 30, 2019. The participants had noninferior mammographic density reduction following 2.5, 5, and 10 mg tamoxifen compared with the median 10.1% decrease observed in the 20 mg group, a reduction confined to premenopausal women. Severe vasomotor symptoms (hot flashes, cold sweats, and night sweats) were reduced by approximately 50% in the 2.5, 5, and 10 mg groups compared with the 20 mg group. CONCLUSION Premenopausal women showed noninferior magnitude of breast density decrease at 2.5 mg of tamoxifen, but fewer side effects compared with the standard dose of 20 mg. Future studies should test whether 2.5 mg of tamoxifen reduces the risk of primary breast cancer." /><meta property="og:image" content="https://6346b314635e8e77d95c6d10--luminous-stardust-9f8aab.netlify.app/media/icon_hu0b7a4cb9992c9ac0e91bd28ffd38dd00_9727_512x512_fill_lanczos_center_3.png" /><meta property="og:locale" content="en-us" />

  
    <meta
      property="article:published_time"
      content="2021-06-10T00:00:00&#43;00:00"
    />
  
  
    <meta property="article:modified_time" content="2021-06-10T00:00:00&#43;00:00">
  






    









<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "Article",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://6346b314635e8e77d95c6d10--luminous-stardust-9f8aab.netlify.app/publication/2021-06-10_low-dose_tamoxifen_f/"
  },
  "headline": "Low-Dose Tamoxifen for Mammographic Density Reduction: A Randomized Controlled Trial",
  
  "datePublished": "2021-06-10T00:00:00Z",
  "dateModified": "2021-06-10T00:00:00Z",
  
  "author": {
    "@type": "Person",
    "name": "Mikael Eriksson"
  },
  
  "publisher": {
    "@type": "Organization",
    "name": "Alessio Crippa",
    "logo": {
      "@type": "ImageObject",
      "url": "https://6346b314635e8e77d95c6d10--luminous-stardust-9f8aab.netlify.app/media/icon_hu0b7a4cb9992c9ac0e91bd28ffd38dd00_9727_192x192_fill_lanczos_center_3.png"
    }
  },
  "description": "PURPOSE Tamoxifen prevents breast cancer in high-risk women and reduces mortality in the adjuvant setting. Mammographic density change is a proxy for tamoxifen therapy response. We tested whether lower doses of tamoxifen were noninferior to reduce mammographic density and associated with fewer symptoms. PATIENTS AND METHODS Women, 40-74 years of age, participating in the Swedish mammography screening program were invited to the 6-month double-blind six-arm randomized placebo-controlled noninferiority dose-determination KARISMA phase II trial stratified by menopausal status (EudraCT 2016-000882-22). In all, 1,439 women were accrued with 1,230 participants accessible for intention-to-treat analysis. The primary outcome was proportion of women treated with placebo, 1, 2.5, 5, and 10 mg whose mammographic density decreased at least as much as the median reduction in the 20 mg arm. The noninferior margin was 17%. Secondary outcome was reduction of symptoms. Post hoc analyses were performed by menopausal status. Per-protocol population and full population were analyzed in sensitivity analysis. RESULTS The 1,439 participants, 566 and 873 pre- and postmenopausal women, respectively, were recruited between October 1, 2016, and September 30, 2019. The participants had noninferior mammographic density reduction following 2.5, 5, and 10 mg tamoxifen compared with the median 10.1% decrease observed in the 20 mg group, a reduction confined to premenopausal women. Severe vasomotor symptoms (hot flashes, cold sweats, and night sweats) were reduced by approximately 50% in the 2.5, 5, and 10 mg groups compared with the 20 mg group. CONCLUSION Premenopausal women showed noninferior magnitude of breast density decrease at 2.5 mg of tamoxifen, but fewer side effects compared with the standard dose of 20 mg. Future studies should test whether 2.5 mg of tamoxifen reduces the risk of primary breast cancer."
}
</script>

  

  




  
  
  

  
  

  


  
  <title>Low-Dose Tamoxifen for Mammographic Density Reduction: A Randomized Controlled Trial | Alessio Crippa</title>

  
  
  
  











</head>


<body id="top" data-spy="scroll" data-offset="70" data-target="#TableOfContents" class="page-wrapper   " data-wc-page-id="e1c0e4061ec489aa5789963502cc5c4e" >

  
  
  
  
  
  
  
  
  
  <script src="/js/wowchemy-init.min.ec9d49ca50e4b80bdb08f0417a28ed84.js"></script>

  


<aside class="search-modal" id="search">
  <div class="container">
    <section class="search-header">

      <div class="row no-gutters justify-content-between mb-3">
        <div class="col-6">
          <h1>Search</h1>
        </div>
        <div class="col-6 col-search-close">
          <a class="js-search" href="#" aria-label="Close"><i class="fas fa-times-circle text-muted" aria-hidden="true"></i></a>
        </div>
      </div>

      <div id="search-box">
        
        <input name="q" id="search-query" placeholder="Search..." autocapitalize="off"
        autocomplete="off" autocorrect="off" spellcheck="false" type="search" class="form-control"
        aria-label="Search...">
        
      </div>

      
      

      

    </section>
    <section class="section-search-results">

      <div id="search-hits">
        
      </div>

    </section>
  </div>
</aside>



  <div class="page-header header--fixed">
    












<header>
  <nav class="navbar navbar-expand-lg navbar-light compensate-for-scrollbar" id="navbar-main">
    <div class="container-xl">

      
      <div class="d-none d-lg-inline-flex">
        <a class="navbar-brand" href="/">Alessio Crippa</a>
      </div>
      

      
      <button type="button" class="navbar-toggler" data-toggle="collapse"
              data-target="#navbar-content" aria-controls="navbar-content" aria-expanded="false" aria-label="Toggle navigation">
      <span><i class="fas fa-bars"></i></span>
      </button>
      

      
      <div class="navbar-brand-mobile-wrapper d-inline-flex d-lg-none">
        <a class="navbar-brand" href="/">Alessio Crippa</a>
      </div>
      

      
      
      <div class="navbar-collapse main-menu-item collapse justify-content-start" id="navbar-content">

        
        <ul class="navbar-nav d-md-inline-flex">
          

          

          
          
          
            
          

          

          
          
          
          

          
            
              
              
            
            
              
              
              
                
              
              
            
          

          <li class="nav-item">
            <a class="nav-link " href="/#about"><span>Home</span></a>
          </li>

          
          

          

          
          
          
            
          

          

          
          
          
          

          
            
              
              
            
            
              
              
              
                
              
              
            
          

          <li class="nav-item">
            <a class="nav-link " href="/#projects"><span>Projects</span></a>
          </li>

          
          

          

          
          
          
            
          

          

          
          
          
          

          
            
              
              
            
            
              
              
              
                
              
              
            
          

          <li class="nav-item">
            <a class="nav-link " href="/#publications"><span>Publications</span></a>
          </li>

          
          

          

          
          
          
            
          

          

          
          
          
          

          
            
              
              
            
            
              
              
              
                
              
              
            
          

          <li class="nav-item">
            <a class="nav-link " href="/#talks"><span>Talks</span></a>
          </li>

          
          

          

          
          
          
            
          

          

          
          
          
          

          
            
              
              
            
            
              
              
              
                
              
              
            
          

          <li class="nav-item">
            <a class="nav-link " href="/#teaching"><span>Teaching</span></a>
          </li>

          
          

          

          
          
          
            
          

          

          
          
          
          

          
            
              
              
            
            
              
              
              
                
              
              
            
          

          <li class="nav-item">
            <a class="nav-link " href="/#software"><span>Software</span></a>
          </li>

          
          

          

          
          
          
            
          

          

          
          
          
          

          
            
              
              
            
            
              
              
              
                
              
              
            
          

          <li class="nav-item">
            <a class="nav-link " href="/#webapp"><span>WebApp</span></a>
          </li>

          
          

          

          
          
          
            
          

          

          
          
          
          

          
            
              
              
            
            
              
              
              
                
              
              
            
          

          <li class="nav-item">
            <a class="nav-link " href="/#contact"><span>Contact</span></a>
          </li>

          
          

        

          
        </ul>
      </div>

      <ul class="nav-icons navbar-nav flex-row ml-auto d-flex pl-md-2">

        
        
          
            
            <li class="nav-item d-none d-lg-inline-flex">
              <a class="nav-link" href="https://twitter.com/AlessioCrippa" data-toggle="tooltip" data-placement="bottom" title="Follow me on Twitter" target="_blank" rel="noopener" aria-label="Follow me on Twitter">
                <i class="fab fa-twitter" aria-hidden="true"></i>
              </a>
            </li>
          
        

        
        
        
        <li class="nav-item">
          <a class="nav-link js-search" href="#" aria-label="Search"><i class="fas fa-search" aria-hidden="true"></i></a>
        </li>
        

        
        
        
        <li class="nav-item dropdown theme-dropdown">
          <a href="#" class="nav-link" data-toggle="dropdown" aria-haspopup="true" aria-label="Display preferences">
            <i class="fas fa-moon" aria-hidden="true"></i>
          </a>
          <div class="dropdown-menu">
            <a href="#" class="dropdown-item js-set-theme-light">
              <span>Light</span>
            </a>
            <a href="#" class="dropdown-item js-set-theme-dark">
              <span>Dark</span>
            </a>
            <a href="#" class="dropdown-item js-set-theme-auto">
              <span>Automatic</span>
            </a>
          </div>
        </li>
        

        
        

      </ul>

    </div>
  </nav>
</header>


  </div>

  <div class="page-body">
    
    
    

    








<div class="pub">

  













  

  
  
  
<div class="article-container pt-3">
  <h1>Low-Dose Tamoxifen for Mammographic Density Reduction: A Randomized Controlled Trial</h1>

  

  
    


<div class="article-metadata">

  
  
  
  
  <div>
    

  <span >
      Mikael Eriksson</span>, <span >
      Martin Eklund</span>, <span >
      Signe Borgquist</span>, <span >
      Roxanna Hellgren</span>, <span >
      Sara Margolin</span>, <span >
      Linda Thoren</span>, <span >
      Ann Rosendahl</span>, <span >
      Kristina Lang</span>, <span >
      Jose Tapia</span>, <span >
      Magnus Backlund</span>, <span >
      Andrea Discacciati</span>, <span >
      Alessio Crippa</span>, <span >
      Marike Gabrielson</span>, <span >
      Mattias Hammarstrom</span>, <span >
      Yvonne Wengstrom</span>, <span >
      Kamila Czene</span>, <span >
      Per Hall</span>
  </div>
  
  

  
  <span class="article-date">
    
    
      
    
    June, 2021
  </span>
  

  

  

  
  
  
  

  
  

</div>

    





  
</div>



  <div class="article-container">

    
    <h3>Abstract</h3>
    <p class="pub-abstract">PURPOSE Tamoxifen prevents breast cancer in high-risk women and reduces mortality in the adjuvant setting. Mammographic density change is a proxy for tamoxifen therapy response. We tested whether lower doses of tamoxifen were noninferior to reduce mammographic density and associated with fewer symptoms. PATIENTS AND METHODS Women, 40-74 years of age, participating in the Swedish mammography screening program were invited to the 6-month double-blind six-arm randomized placebo-controlled noninferiority dose-determination KARISMA phase II trial stratified by menopausal status (EudraCT 2016-000882-22). In all, 1,439 women were accrued with 1,230 participants accessible for intention-to-treat analysis. The primary outcome was proportion of women treated with placebo, 1, 2.5, 5, and 10 mg whose mammographic density decreased at least as much as the median reduction in the 20 mg arm. The noninferior margin was 17%. Secondary outcome was reduction of symptoms. Post hoc analyses were performed by menopausal status. Per-protocol population and full population were analyzed in sensitivity analysis. RESULTS The 1,439 participants, 566 and 873 pre- and postmenopausal women, respectively, were recruited between October 1, 2016, and September 30, 2019. The participants had noninferior mammographic density reduction following 2.5, 5, and 10 mg tamoxifen compared with the median 10.1% decrease observed in the 20 mg group, a reduction confined to premenopausal women. Severe vasomotor symptoms (hot flashes, cold sweats, and night sweats) were reduced by approximately 50% in the 2.5, 5, and 10 mg groups compared with the 20 mg group. CONCLUSION Premenopausal women showed noninferior magnitude of breast density decrease at 2.5 mg of tamoxifen, but fewer side effects compared with the standard dose of 20 mg. Future studies should test whether 2.5 mg of tamoxifen reduces the risk of primary breast cancer.</p>
    

    
    
    <div class="row">
      <div class="col-md-1"></div>
      <div class="col-md-10">
        <div class="row">
          <div class="col-12 col-md-3 pub-row-heading">Type</div>
          <div class="col-12 col-md-9">
            <a href="/publication/#2">
              Journal article
            </a>
          </div>
        </div>
      </div>
      <div class="col-md-1"></div>
    </div>
    <div class="d-md-none space-below"></div>
    

    
    <div class="row">
      <div class="col-md-1"></div>
      <div class="col-md-10">
        <div class="row">
          <div class="col-12 col-md-3 pub-row-heading">Publication</div>
          <div class="col-12 col-md-9">Journal of Clinical Oncology, 39Article (17) 1899&ndash;1908. <a href="https://doi.org/10.1200/JCO.20.02598" target="_blank" rel="noopener">https://doi.org/10.1200/JCO.20.02598</a></div>
        </div>
      </div>
      <div class="col-md-1"></div>
    </div>
    <div class="d-md-none space-below"></div>
    

    <div class="space-below"></div>

    <div class="article-style"></div>

    







<div class="share-box">
  <ul class="share">
    
      
      
      
        
      
      
      
      
      
      
      
      <li>
        <a href="https://twitter.com/intent/tweet?url=https%3A%2F%2F6346b314635e8e77d95c6d10--luminous-stardust-9f8aab.netlify.app%2Fpublication%2F2021-06-10_low-dose_tamoxifen_f%2F&amp;text=Low-Dose&#43;Tamoxifen&#43;for&#43;Mammographic&#43;Density&#43;Reduction%3A&#43;A&#43;Randomized&#43;Controlled&#43;Trial" target="_blank" rel="noopener" class="share-btn-twitter" aria-label="twitter">
          <i class="fab fa-twitter"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      
      
      
      
      <li>
        <a href="https://www.facebook.com/sharer.php?u=https%3A%2F%2F6346b314635e8e77d95c6d10--luminous-stardust-9f8aab.netlify.app%2Fpublication%2F2021-06-10_low-dose_tamoxifen_f%2F&amp;t=Low-Dose&#43;Tamoxifen&#43;for&#43;Mammographic&#43;Density&#43;Reduction%3A&#43;A&#43;Randomized&#43;Controlled&#43;Trial" target="_blank" rel="noopener" class="share-btn-facebook" aria-label="facebook">
          <i class="fab fa-facebook"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      
      
      
      
        
      
      <li>
        <a href="mailto:?subject=Low-Dose%20Tamoxifen%20for%20Mammographic%20Density%20Reduction%3A%20A%20Randomized%20Controlled%20Trial&amp;body=https%3A%2F%2F6346b314635e8e77d95c6d10--luminous-stardust-9f8aab.netlify.app%2Fpublication%2F2021-06-10_low-dose_tamoxifen_f%2F" target="_blank" rel="noopener" class="share-btn-email" aria-label="envelope">
          <i class="fas fa-envelope"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      
      
      
      
      <li>
        <a href="https://www.linkedin.com/shareArticle?url=https%3A%2F%2F6346b314635e8e77d95c6d10--luminous-stardust-9f8aab.netlify.app%2Fpublication%2F2021-06-10_low-dose_tamoxifen_f%2F&amp;title=Low-Dose&#43;Tamoxifen&#43;for&#43;Mammographic&#43;Density&#43;Reduction%3A&#43;A&#43;Randomized&#43;Controlled&#43;Trial" target="_blank" rel="noopener" class="share-btn-linkedin" aria-label="linkedin-in">
          <i class="fab fa-linkedin-in"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      
      
      
      
      <li>
        <a href="whatsapp://send?text=Low-Dose&#43;Tamoxifen&#43;for&#43;Mammographic&#43;Density&#43;Reduction%3A&#43;A&#43;Randomized&#43;Controlled&#43;Trial%20https%3A%2F%2F6346b314635e8e77d95c6d10--luminous-stardust-9f8aab.netlify.app%2Fpublication%2F2021-06-10_low-dose_tamoxifen_f%2F" target="_blank" rel="noopener" class="share-btn-whatsapp" aria-label="whatsapp">
          <i class="fab fa-whatsapp"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      
      
      
      
      <li>
        <a href="https://service.weibo.com/share/share.php?url=https%3A%2F%2F6346b314635e8e77d95c6d10--luminous-stardust-9f8aab.netlify.app%2Fpublication%2F2021-06-10_low-dose_tamoxifen_f%2F&amp;title=Low-Dose&#43;Tamoxifen&#43;for&#43;Mammographic&#43;Density&#43;Reduction%3A&#43;A&#43;Randomized&#43;Controlled&#43;Trial" target="_blank" rel="noopener" class="share-btn-weibo" aria-label="weibo">
          <i class="fab fa-weibo"></i>
        </a>
      </li>
    
  </ul>
</div>











  
  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
















  </div>
</div>
  </div>

  <div class="page-footer">
    
    
    <div class="container">
      <footer class="site-footer">

  












  
  
  
  
  













  
  
  

  
  
    
  
  
    
  

  

  
  <p class="powered-by copyright-license-text">
    © 2022 Me. This work is licensed under <a href="https://creativecommons.org/licenses/by-nc-nd/4.0" rel="noopener noreferrer" target="_blank">CC BY NC ND 4.0</a>
  </p>
  

  <p class="powered-by footer-license-icons">
    <a href="https://creativecommons.org/licenses/by-nc-nd/4.0" rel="noopener noreferrer" target="_blank" aria-label="Creative Commons">
      <i class="fab fa-creative-commons fa-2x" aria-hidden="true"></i>
      <i class="fab fa-creative-commons-by fa-2x" aria-hidden="true"></i>
      
        <i class="fab fa-creative-commons-nc fa-2x" aria-hidden="true"></i>
      
      
        <i class="fab fa-creative-commons-nd fa-2x" aria-hidden="true"></i>
      
    </a>
  </p>





  <p class="powered-by">
    
    
    
      
      
      
      
      
      
      Published with <a href="https://wowchemy.com/?utm_campaign=poweredby" target="_blank" rel="noopener">Wowchemy</a> — the free, <a href="https://github.com/wowchemy/wowchemy-hugo-themes" target="_blank" rel="noopener">open source</a> website builder that empowers creators.
    
  </p>
</footer>

    </div>
    
  </div>

  


<script src="/js/vendor-bundle.min.d26509351aa0ff874abbee824e982e9b.js"></script>




  

  
  

  













  
  <script id="search-hit-fuse-template" type="text/x-template">
    <div class="search-hit" id="summary-{{key}}">
      <div class="search-hit-content">
        <div class="search-hit-name">
          <a href="{{relpermalink}}">{{title}}</a>
          <div class="article-metadata search-hit-type">{{type}}</div>
          <p class="search-hit-description">{{snippet}}</p>
        </div>
      </div>
    </div>
  </script>
  
    <script src="https://cdn.jsdelivr.net/gh/krisk/Fuse@v3.2.1/dist/fuse.min.js" integrity="sha512-o38bmzBGX+hD3JHWUFCDA09btWaqrNmoJ3RXLlrysA7PP01Kgs4UlE4MhelE1v5dJR3+cxlR4qQlotsW7jKsnw==" crossorigin="anonymous"></script>
    <script src="https://cdn.jsdelivr.net/gh/julmot/mark.js@8.11.1/dist/jquery.mark.min.js" integrity="sha512-mhbv5DqBMgrWL+32MmsDOt/OAvqr/cHimk6B8y/bx/xS88MVkYGPiVv2ixKVrkywF2qHplNRUvFsAHUdxZ3Krg==" crossorigin="anonymous"></script>
  












  
  
  
  
  
  
  







<script id="page-data" type="application/json">{"use_headroom":true}</script>



  <script src="/js/wowchemy-headroom.db4755770454eb63685f8de785c0a172.js" type="module"></script>









  
  


<script src="/en/js/wowchemy.min.e8ee06ba8371980ffde659871dd593b0.js"></script>







  
<div id="modal" class="modal fade" role="dialog">
  <div class="modal-dialog">
    <div class="modal-content">
      <div class="modal-header">
        <h5 class="modal-title">Cite</h5>
        <button type="button" class="close" data-dismiss="modal" aria-label="Close">
          <span aria-hidden="true">&times;</span>
        </button>
      </div>
      <div class="modal-body">
        
        <pre><code></code></pre>
      </div>
      <div class="modal-footer">
        <a class="btn btn-outline-primary my-1 js-copy-cite" href="#" target="_blank">
          <i class="fas fa-copy"></i> Copy
        </a>
        <a class="btn btn-outline-primary my-1 js-download-cite" href="#" target="_blank">
          <i class="fas fa-download"></i> Download
        </a>
        <div id="modal-error"></div>
      </div>
    </div>
  </div>
</div>


  <script src="/js/wowchemy-publication.68f8d7090562ca65fc6d3cb3f8f2d2cb.js" type="module"></script>


















</body>
</html>
